Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Ireland

Marie Skłodowska-Curie Action · Running

GLIORESOLVE Training the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironment

Coordinator
Royal College of Surgeons in Ireland, Ireland
Runs
1 September 2022 to 31 August 2026
Status
Running
EU funding
€2.7m
Total cost
—
Partners
24 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101073386

What the project is doing

In the project's own words, from its summary on CORDIS.

Isocitrate dehydrogenase wildtype (IDHwt) glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. Effective precision medicine therapies are thus urgently required. This can only be achieved by focused multi-sectoral collaborations in innovative research disciplines. Overall, GLIORESOLVE will exploit the intractability of GBM to address European applied biomedical research training needs and will train 10 innovative, entrepreneurial doctoral researchers (DRs).

The research objectives of GLIORESOLVE are i) to extend immunotherapy options to IDHwt GBM patients and identify novel tumour microenvironment (TME) subtype-specific therapeutic targets, (ii) develop and optimise state of the art pre-clinical models that recapitulate GBM TME-subtypes and (iii) test novel rationally selected (available) drugs / drug combinations for precision treatment of IDHwt GBM based on TME subtype assignment.

Cumulatively, the programme seeks to generate sufficient data to support a post-project Phase 2 clinical trial. The consortium brings together leading European academics, clinicians, private sector and not-for-profit partners, and incorporates disruptive research methods including multi-omics, ex-vivo ‘tumour-on-a-chip’ assay development, computational modelling and systems biology. Overall GLIORESOLVE provides a comprehensive translational research strategy that goes significantly beyond the current state-of-the-art in neuro-oncology, to establish a new TME-targeting precision medicine platform for this incurable disease.

The GLIORESOLVE network addresses current needs in academia and the private sector to train doctoral researchers in an environment that spans multiple disciplines. Thus, GLIORESOLVE DRs will be able to navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Topics

Who is involved

OrganisationCityCountryRole
Royal College of Surgeons in IrelandDublin 2IrelandCoordinator
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Vib VzwZwijnaarde - GentBelgiumParticipant
Mount Sinai HospitalTorontoCanadaAssociatedpartner
Bayer AktiengesellschaftLeverkusenGermanyParticipant
Charite - Universitaetsmedizin BerlinBerlinGermanyAssociatedpartner
Genexplain GmbHWolfenbuttelGermanyParticipant
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyAssociatedpartner
Miltenyi Biotec BV & Co KgBergisch GladbachGermanyAssociatedpartner
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyParticipant
Sb Science Management UGBerlinGermanyAssociatedpartner
Arjuna Therapeutics S.L.Ames (A Coruña)SpainAssociatedpartner
CartheraParisFranceAssociatedpartner
Institut Du Cerveau Et De La Moelle EpiniereParisFranceParticipant
Sorbonne UniversiteParisFranceAssociatedpartner
Laboratoire National De SanteDudelangeLuxembourgAssociatedpartner
Luxembourg Institute of HealthStrassenLuxembourgParticipant
Universite Du LuxembourgEsch-Sur-AlzetteLuxembourgAssociatedpartner
Erasmus Universitair Medisch Centrum RotterdamRotterdamNetherlandsParticipant
Mimetas BVLeidenNetherlandsParticipant
Oslo Universitetssykehus HfOsloNorwayAssociatedpartner
International Brain Tumour AllianceLondonUnited KingdomAssociatedpartner
The University of EdinburghEdinburghUnited KingdomAssociatedpartner
Brigham IncBostonUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI